Emmaus Life Sciences (Emmaus Life Sciences) 5-Year EBITDA Growth Rate : 0.00% (As of Sep. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Emmaus Life Sciences 5-Year EBITDA Growth Rate?

Emmaus Life Sciences's EBITDA per Share for the three months ended in Sep. 2023 was $0.02.

During the past 3 years, the average EBITDA Per Share Growth Rate was 44.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Emmaus Life Sciences was 79.60% per year. The lowest was -622.50% per year. And the median was 27.80% per year.

Competitive Comparison of Emmaus Life Sciences's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Emmaus Life Sciences's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's 5-Year EBITDA Growth Rate falls into.

Emmaus Life Sciences 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Emmaus Life Sciences (OTCPK:EMMA) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Emmaus Life Sciences 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Emmaus Life Sciences's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Emmaus Life Sciences (Emmaus Life Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Emmaus Life Sciences Inc (OTCPK:EMMA) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503

Website

https://www.emmausmedical.com

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies primarily for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Executives

Seah H. Lim	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Willis C Lee	director, officer: Vice Chairman & COO	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Yutaka Niihara	director, 10 percent owner, officer: Chairman and CEO	20725 S. WESTERN BLVD., SUITE 136, TORRANCE CA 90501
Lori Teranishi	director	1000 BISHOP STREET, SUITE 500, HONOLULU HI 96813
Charles William Stark	officer: SVP, Clinical Development	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
George Sekulich	officer: CIO & SVP	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lui Alfred Fu Kong	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Jane Pine Wood	director	956 MAIN STREET, DENNIS MA 02638
Wei Peu Zen	director	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Sherwood Joseph Charles Iii	officer: Chief Financial Officer	21250 HAWTHORNE BLVD., SUITE 800, TORRANCE CA 90503
Masaharu Osato	director	3440 LOMITA BOULEVARD, SUITE 320, TORRANCE CA 90505
Ian Harvey Zwicker	director	21250 HAWTHORNE BOULEVARD, SUITE 800, TORRANCE CA 90503
Lan T. Tran	officer: Chief Administrative Officer	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501
Robert Iv Dickey	director	320 WEST MERMAID LANE, PHILADELPHIA PA 19118
Yasushi Nagasaki	officer: Sr. VP Finance	20725 S. WESTERN AVE., SUITE 136, TORRANCE CA 90501